KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash from Investing Activities (2016 - 2025)

Inovio Pharmaceuticals' Cash from Investing Activities history spans 16 years, with the latest figure at $8.9 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 37.01% year-over-year to $8.9 million; the TTM value through Sep 2025 reached $48.7 million, down 45.46%, while the annual FY2024 figure was $104.1 million, 19.13% up from the prior year.
  • Cash from Investing Activities for Q3 2025 was $8.9 million at Inovio Pharmaceuticals, up from $5.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $56.0 million in Q3 2021 and bottomed at -$275.1 million in Q1 2021.
  • The 5-year median for Cash from Investing Activities is $19.0 million (2023), against an average of $7.4 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 431.02% in 2021 before it soared 931.55% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$6.5 million in 2021, then skyrocketed by 931.55% to $54.0 million in 2022, then crashed by 63.07% to $19.9 million in 2023, then surged by 73.71% to $34.6 million in 2024, then crashed by 74.4% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Cash from Investing Activities are $8.9 million (Q3 2025), $5.3 million (Q2 2025), and -$51753.0 (Q1 2025).